Despite these limitations there is now strong evidence that TMB correlates with durable responses to PD-1 blockade in multiple tumor types and with further standardization TMB will likely be a reliable surrogate to predict immunotherapy response. The gene discussed is PDCD1; the disease is neoplasm.